Clinical trial
The Efficacy of Oxybutynin Chloride OROS in Patient-Reported Outcomes With Dose Escalation in Korean Overactive Bladder Patients
NCT00613327 is registered in ClinicalTrials.gov with Janssen Korea, Ltd., Korea as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- The Efficacy of Oxybutynin Chloride OROS in Patient-Reported Outcomes With Dose Escalation in Korean Overactive Bladder Patients
- Lead sponsor
- Janssen Korea, Ltd., Korea
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- September 30, 2007
- Completion date
- June 30, 2008
- Enrollment
- 345 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.